465 related articles for article (PubMed ID: 28155650)
1. Estimating survival time of patients with glioblastoma multiforme and characterization of the identified microRNA signatures.
Yerukala Sathipati S; Huang HL; Ho SY
BMC Genomics; 2016 Dec; 17(Suppl 13):1022. PubMed ID: 28155650
[TBL] [Abstract][Full Text] [Related]
2. PI3 kinase pathway regulated miRNome in glioblastoma: identification of miR-326 as a tumour suppressor miRNA.
Nawaz Z; Patil V; Paul Y; Hegde AS; Arivazhagan A; Santosh V; Somasundaram K
Mol Cancer; 2016 Nov; 15(1):74. PubMed ID: 27871300
[TBL] [Abstract][Full Text] [Related]
3. Identifying the miRNA signature associated with survival time in patients with lung adenocarcinoma using miRNA expression profiles.
Yerukala Sathipati S; Ho SY
Sci Rep; 2017 Aug; 7(1):7507. PubMed ID: 28790336
[TBL] [Abstract][Full Text] [Related]
4. Relationship between magnetic resonance imaging features and miRNA gene expression in patients with glioblastoma multiforme.
Li WB; Chen HY; Zhang W; Yan W; Shi R; Li SW; Jiang T
Chin Med J (Engl); 2013; 126(15):2881-5. PubMed ID: 23924460
[TBL] [Abstract][Full Text] [Related]
5. Bioinformatics analysis of miRNA expression profile between primary and recurrent glioblastoma.
Bo LJ; Wei B; Li ZH; Wang ZF; Gao Z; Miao Z
Eur Rev Med Pharmacol Sci; 2015 Oct; 19(19):3579-86. PubMed ID: 26502847
[TBL] [Abstract][Full Text] [Related]
6. A three-microRNA signature identifies two subtypes of glioblastoma patients with different clinical outcomes.
Marziali G; Buccarelli M; Giuliani A; Ilari R; Grande S; Palma A; D'Alessandris QG; Martini M; Biffoni M; Pallini R; Ricci-Vitiani L
Mol Oncol; 2017 Sep; 11(9):1115-1129. PubMed ID: 28248456
[TBL] [Abstract][Full Text] [Related]
7. MicroRNA expression signatures and their correlation with clinicopathological features in glioblastoma multiforme.
Henriksen M; Johnsen KB; Olesen P; Pilgaard L; Duroux M
Neuromolecular Med; 2014 Sep; 16(3):565-77. PubMed ID: 24817689
[TBL] [Abstract][Full Text] [Related]
8. MicroRNA-target cross-talks: Key players in glioblastoma multiforme.
Toraih EA; Aly NM; Abdallah HY; Al-Qahtani SA; Shaalan AA; Hussein MH; Fawzy MS
Tumour Biol; 2017 Nov; 39(11):1010428317726842. PubMed ID: 29110584
[TBL] [Abstract][Full Text] [Related]
9. Identification of the miRNA signature associated with survival in patients with ovarian cancer.
Sathipati SY; Ho SY
Aging (Albany NY); 2021 Apr; 13(9):12660-12690. PubMed ID: 33910165
[TBL] [Abstract][Full Text] [Related]
10. Five miRNAs considered as molecular targets for predicting neuroglioma.
Yang H; Wang Y
Tumour Biol; 2016 Jan; 37(1):1051-9. PubMed ID: 26269115
[TBL] [Abstract][Full Text] [Related]
11. Simultaneous miRNA and mRNA transcriptome profiling of glioblastoma samples reveals a novel set of OncomiR candidates and their target genes.
Gulluoglu S; Tuysuz EC; Sahin M; Kuskucu A; Kaan Yaltirik C; Ture U; Kucukkaraduman B; Akbar MW; Gure AO; Bayrak OF; Dalan AB
Brain Res; 2018 Dec; 1700():199-210. PubMed ID: 30176243
[TBL] [Abstract][Full Text] [Related]
12. Cancer survival classification using integrated data sets and intermediate information.
Kim S; Park T; Kon M
Artif Intell Med; 2014 Sep; 62(1):23-31. PubMed ID: 24997860
[TBL] [Abstract][Full Text] [Related]
13. Prediction of a competing endogenous RNA co-expression network as a prognostic marker in glioblastoma.
Peng Q; Li R; Li Y; Xu X; Ni W; Lin H; Ning L
J Cell Mol Med; 2020 Nov; 24(22):13346-13355. PubMed ID: 33047898
[TBL] [Abstract][Full Text] [Related]
14. A 4-miRNA signature to predict survival in glioblastomas.
Hermansen SK; Sørensen MD; Hansen A; Knudsen S; Alvarado AG; Lathia JD; Kristensen BW
PLoS One; 2017; 12(11):e0188090. PubMed ID: 29136645
[TBL] [Abstract][Full Text] [Related]
15. Interactions of miR-323/miR-326/miR-329 and miR-130a/miR-155/miR-210 as prognostic indicators for clinical outcome of glioblastoma patients.
Qiu S; Lin S; Hu D; Feng Y; Tan Y; Peng Y
J Transl Med; 2013 Jan; 11():10. PubMed ID: 23302469
[TBL] [Abstract][Full Text] [Related]
16. Dysregulated miR-671-5p / CDR1-AS / CDR1 / VSNL1 axis is involved in glioblastoma multiforme.
Barbagallo D; Condorelli A; Ragusa M; Salito L; Sammito M; Banelli B; Caltabiano R; Barbagallo G; Zappalà A; Battaglia R; Cirnigliaro M; Lanzafame S; Vasquez E; Parenti R; Cicirata F; Di Pietro C; Romani M; Purrello M
Oncotarget; 2016 Jan; 7(4):4746-59. PubMed ID: 26683098
[TBL] [Abstract][Full Text] [Related]
17. Identifying dysfunctional miRNA-mRNA regulatory modules by inverse activation, cofunction, and high interconnection of target genes: a case study of glioblastoma.
Xiao Y; Ping Y; Fan H; Xu C; Guan J; Zhao H; Li Y; Lv Y; Jin Y; Wang L; Li X
Neuro Oncol; 2013 Jul; 15(7):818-28. PubMed ID: 23516263
[TBL] [Abstract][Full Text] [Related]
18. hsa-miR-9 controls the mobility behavior of glioblastoma cells via regulation of MAPK14 signaling elements.
Ben-Hamo R; Zilberberg A; Cohen H; Efroni S
Oncotarget; 2016 Apr; 7(17):23170-81. PubMed ID: 27036038
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA signature for estimating the survival time in patients with bladder urothelial carcinoma.
Yerukala Sathipati S; Tsai MJ; Shukla SK; Ho SY; Liu Y; Beheshti A
Sci Rep; 2022 Mar; 12(1):4141. PubMed ID: 35264666
[TBL] [Abstract][Full Text] [Related]
20. Uncovering MicroRNA and Transcription Factor Mediated Regulatory Networks in Glioblastoma.
Sun J; Gong X; Purow B; Zhao Z
PLoS Comput Biol; 2012; 8(7):e1002488. PubMed ID: 22829753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
